- Home
- NAMS vs XENE Comparison
NAMS vs XENE Comparison
Compare NAMS & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NAMS | XENE |
|---|---|---|
| Founded | 2019 | 1996 |
| Country | Netherlands | Canada |
| Employees | 100 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.2B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | NAMS | XENE |
|---|---|---|
| Price | $34.77 | $59.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 12 |
| Target Price | $46.75 | ★ $67.17 |
| AVG Volume (30 Days) | 809.9K | ★ 977.9K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $311,000.00 |
| Revenue This Year | $17.96 | N/A |
| Revenue Next Year | $540.65 | $2,436.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.82 | $28.19 |
| 52 Week High | $42.00 | $62.91 |
Technical Indicators
Market Signals| Indicator | NAMS | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 57.13 | 65.77 |
| Support Level | $34.05 | $39.93 |
| Resistance Level | $37.43 | $62.91 |
| Average True Range (ATR) | 1.75 | 1.81 |
| MACD | 0.19 | -0.18 |
| Stochastic Oscillator | 74.13 | 92.31 |
Price Performance
Historical ComparisonAbout NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.